SAIPARENT

Financial Performance - Consolidated revenue from operations for Q2 FY27 rose 9% sequentially to INR196 crores, with H1 FY27 revenue at INR376 crores. - Gross margin improved significantly to 47.5% in Q2 FY27 compared to 40.9% in Q1 FY27, driven by tighter inventory management. - EBITDA grew 67% sequentially to INR41 crores, with an EBITDA margin of 21.1%. - Profit after tax (PAT) grew to INR10.5 crores in Q2 FY27. Project Execution & Acquisitions - Saicriti Pharma injectable facility build is progressing towards a July 2027 completion target, funded by IPO proceeds and project debt. - Sai Prathyak Laboratories acquisition is complete, now operating as the group's dedicated R&D subsidiary with 28 research scientists, and is set to commence external CRO contracts. - Adelaide facility is expected to be commissioned in January 2027, moving outsourced volumes in-house. - Board approved acquiring the remaining 25% stake in SP Analytics Private Limited to make it a wholly owned subsidiary. Management Guidance & Outlook - Management remains confident of comfortably crossing the full-year revenue target of INR750 crores and maintaining EBITDA margins above 17%. - FY28 is projected to be the year when the results of current capital investments and new revenue streams will fully reflect in performance.

Current scenario Consolidated revenue from operations rose 9% sequentially to INR196 crores for Q2 FY27; H1 FY27 revenue stood at INR376 crores. Gross margin improved from 40.9% in Q1 to 47.5% in Q2 due to tighter inventory management and strict first-in-first-out controls. EBITDA grew 67% sequentially to INR41 crores with an EBITDA margin of 21.1% against 13.7% in Q1; H1 EBITDA stood at INR66 crores (17.6% margin). PAT grew 33% sequentially to INR10.5 crores for Q2 and INR18.4 crores for H1. Changes in trends Invested INR98.8 crores of IPO proceeds into two acquisitions (Saicriti Pharma and Sai Prathyak Laboratories) for 60% stakes to build EU GMP-compliant injectable capacity and an R&D platform. Unit III expansion at Bhongir is nearing completion, with the new block commencing from December 2026 to boost production capacity by 81%. Management Guidance & Outlook Reaffirmed full-year FY27 revenue target of INR750 crores, expecting to comfortably cross it, with margins remaining above the guided 17%. Saicriti Pharma facility is targeted for completion in July 2027, with exports commencing from FY28. Adelaide manufacturing facility is expected to be commissioned in January 2027, with commercial supply starting in Q1 FY28. Sai Prathyak Laboratories will transition from an in-house cost center to a revenue-generating model starting from Q4 FY27 and Q1 FY28.

- Sai Parenterals Limited has informed the stock exchanges about the availability of the audio recording for the earnings call. - The earnings call was held on November 2, 2026, for the Q2 results ended September 30, 2026. - The audio recording link has been provided for investor and public reference.

- Over 50% contracted revenue backed by long-term regulated market agreements. - Secured AUD 232 mn Australian OTC supply and USD 11 mn 4-year Philippines contract. - Undertaking ₹571 Cr capex programme (₹440 Cr company-funded) to expand capacity from 1,160 mn to 1,469 mn units p.a.

- Q2 FY27 Consolidated Revenue reached ₹196.1 Cr vs ₹54.9 Cr YoY, with EBITDA at ₹41.4 Cr and PAT at ₹10.5 Cr. - Completed 60% stake acquisitions in Saicriti Pharma and Sai Prathyak Laboratories using IPO proceeds. - Unit III expansion completed; company remains on track for FY27 revenue target of ₹750 Cr.

Q2 FY27 Consolidated Revenue ₹194.92Cr vs ₹53.53Cr (▲264% YoY) EBITDA ₹40.24Cr vs ₹11.42Cr (▲252% YoY) PAT ₹10.51Cr vs ₹6.35Cr (▲66% YoY) EBITDA Margin 20.6% vs 21.3% (▼70bps) - Board approved acquisition of the remaining 25% equity stake in subsidiary SP Analytics Pvt Ltd for ₹25,000, making it a wholly-owned subsidiary. - Completed acquisition of 60% equity stake in Saicriti Pharma Pvt Ltd, making it a subsidiary. - Constituted a Management Committee for operational convenience.

Q2 FY27 Consolidated Revenue ₹194.92Cr vs ₹53.53Cr (▲264% YoY) EBITDA ₹40.24Cr vs ₹11.42Cr (▲252% YoY) PAT ₹10.51Cr vs ₹6.35Cr (▲66% YoY) EBITDA Margin 20.6% vs 21.3% (▼69bps)

Concall Schedule Concall Date: Monday, November 2, 2026 Concall Time: 2:00 PM (IST)

Sai Parenterals completed the acquisition of a 60% equity stake in Prathyak Laboratories (renamed Sai Prathyak Laboratories) for Rs. 15 crore, funded from IPO proceeds. - The acquisition replaces a planned greenfield R&D facility, providing an operational research centre at Genome Valley, Hyderabad. - Prathyak brings 28 research scientists and a pipeline of 150 SKUs across 86 molecules in complex injectables and oncology. - The company holds a Right of First Refusal (ROFR) to acquire the remaining 40% stake at the same valuation from internal accruals.

Concall Schedule Concall Date: 14th October 2026 (Wednesday) Concall Time: 11:00 am onwards

- Sai Parenterals Limited accepted the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer effective 30th September 2026 due to personal reasons. - Appointed Mr. Ashwani Singh Bisht as the new Company Secretary & Compliance Officer w.e.f. 30th September 2026. - Appointed Mr. Arvind Gannimitta as the Chief Operating Officer w.e.f. 30th September 2026.

- Resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer effective September 30, 2026. - Appointment of Mr. Ashwani Singh Bisht as the new Company Secretary & Compliance Officer w.e.f. September 30, 2026. - Appointment of Mr. Arvind Gannimitta as the Chief Operating Officer w.e.f. September 30, 2026.

- The 25th Annual General Meeting (AGM) of Sai Parenterals Limited was held on September 10, 2026, via video conferencing. - All 12 proposed resolutions were passed. - Key resolutions included adoption of FY26 financial statements, re-appointment of Anil Kumar Karusala as Managing Director and Vijitha Gorrepati as Whole-Time Director. - Other approvals covered variation in IPO proceeds utilization, ESOP schemes, related party transactions, and ratification of cost auditor remuneration.